Create Free Account

By creating account you will get access to hot stocks & personalised emails

Allakos Inc

Healthcare US ALLK

1.255USD
0.18(17.29%)

Last update at 2024-12-19T18:56:00Z

Day Range

1.121.34
LowHigh

52 Week Range

0.543.40
LowHigh

Fundamentals

  • Previous Close 1.07
  • Market Cap96.49M
  • Volume556136
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-154.72301M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.03

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -319.95200M -269.86000M -153.48000M -85.37200M -43.53800M
Minority interest - - - - -
Net income -317.47500M -267.17300M -147.62200M -77.66300M -43.53800M
Selling general administrative 57.35M 75.15M 51.52M 29.56M 12.43M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 7.07M 2.31M 1.54M 1.51M 0.24M
Ebit -329.50000M -273.78500M -158.60200M -92.92600M -45.96300M
Ebitda -322.42900M -271.47500M -157.05700M -91.41800M -45.72100M
Depreciation and amortization 7.07M 2.31M 1.54M 1.51M 0.24M
Non operating income net other -1.32700M 1.08M -0.86500M -0.15500M -0.19200M
Operating income -322.42900M -271.47500M -157.05700M -91.41800M -45.72100M
Other operating expenses 322.43M 271.48M 157.06M 91.42M 45.72M
Interest expense 3.67M 2.31M 4.31M 6.20M 2.38M
Tax provision - - - 0.00000M 0.00000M
Interest income 3.67M 0.38M 4.31M 6.20M 2.38M
Net interest income 3.67M 0.38M 4.31M 6.20M 2.38M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.47700M -2.68700M -5.85800M -7.70900M 2.18M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 322.43M 271.48M 157.06M 91.42M 45.72M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.48M 1.61M 3.58M 6.05M -0.19200M
Discontinued operations - - - - -
Net income from continuing ops -320.08300M -270.02100M -153.60900M -85.37200M -43.53800M
Net income applicable to common shares -319.95200M -269.86000M -153.48000M -85.37200M -43.53800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 243.61M 386.42M 534.82M 719.62M 516.89M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.10M 29.06M 27.34M 10.27M 3.97M
Total liab 74.79M 75.99M 89.35M 65.22M 21.17M
Total stockholder equity 168.82M 310.43M 445.48M 654.39M 495.72M
Deferred long term liab - - - - -
Other current liab 33.33M 22.05M 4.85M 0.09M 0.09M
Common stock 0.09M 0.09M 0.05M 0.05M 0.05M
Capital stock 0.09M 0.09M 0.05M 0.05M 0.05M
Retained earnings -1118.47700M -932.77600M -612.82400M -342.96400M -189.48400M
Other liab - - - - 8.11M
Good will - - - - -
Other assets - 8.21M 8.44M 2.27M 2.84M
Cash 66.44M 87.22M 152.82M 207.18M 38.37M
Cash and equivalents - - - - -
Total current liabilities 36.58M 30.04M 40.25M 22.45M 13.06M
Current deferred revenue -1.76400M - 19.39M 7.91M 6.60M
Net debt -24.97500M -38.10700M -103.72300M -164.40400M -29.84500M
Short term debt 3.25M 3.16M 2.32M 0.49M 0.41M
Short long term debt - - - - -
Short long term debt total 41.47M 49.11M 49.10M 42.77M 8.52M
Other stockholder equity 1287.16M 1243.41M 1058.40M 997.30M 685.02M
Property plant equipment - 39.14M 43.10M 8.35M 14.19M
Total current assets 179.89M 308.84M 451.58M 669.27M 499.87M
Long term investments - - - - -
Net tangible assets - 310.43M 445.48M 654.39M 495.72M
Short term investments 104.35M 192.57M 271.42M 451.82M 457.53M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.76M 4.83M 13.69M 13.96M 5.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.05M -0.28400M -0.15300M 0.00800M 0.14M
Additional paid in capital - - - - -
Common stock total equity - 0.09M 0.05M 0.05M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -932.77600M -612.82400M -342.96400M -189.48400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.74M 8.21M 8.44M 2.27M 2.84M
Deferred long term asset charges - - - - -
Non current assets total 63.72M 77.58M 83.24M 50.35M 17.02M
Capital lease obligations 41.47M 49.11M 51.41M 43.27M 0.41M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 78.84M 176.46M 4.53M -311.20100M -144.10100M
Change to liabilities -7.61300M 13.36M 8.54M 7.58M 2.84M
Total cashflows from investing activities 71.68M 143.24M 3.90M -311.97100M -151.04700M
Net borrowings - - - - 0.05M
Total cash from financing activities 141.88M 10.26M 278.84M 381.16M 138.75M
Change to operating activities -5.00300M 4.96M -6.23100M 3.91M 1.59M
Net income -319.95200M -269.86000M -153.48000M -85.37200M -43.53800M
Change in cash -66.40800M -54.35500M 168.81M 6.18M -50.74500M
Begin period cash flow 155.10M 209.45M 40.64M 34.46M 85.21M
End period cash flow 88.69M 155.10M 209.45M 40.64M 34.46M
Total cash from operating activities -279.97100M -207.85300M -113.92400M -63.01200M -38.45000M
Issuance of capital stock 140.59M 0.00000M 271.69M 377.52M 138.36M
Depreciation 7.07M 2.31M 1.54M 1.51M 0.24M
Other cashflows from investing activities 1.17M - - -311.20100M -144.10100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 141.88M 10.26M 278.84M 381.16M 0.02M
Other cashflows from financing activities 1.29M 8.49M 7.15M 379.97M 0.37M
Change to netincome 43.19M 50.89M 33.45M 15.76M 4.57M
Capital expenditures 8.33M 33.22M 0.63M 0.77M 6.95M
Change receivables - - - - -
Cash flows other operating -3.25100M -7.94200M -6.33700M 0.17M -1.25800M
Exchange rate changes - - - - -
Cash and cash equivalents changes -66.40800M -54.35500M 168.81M 6.18M -50.74500M
Change in working capital -13.76800M 4.72M 1.41M 7.48M 1.67M
Stock based compensation 43.16M 50.84M 33.45M 15.76M 4.57M
Other non cash items 3.52M 0.70M 0.79M 0.28M -1.39200M
Free cash flow -288.30400M -241.07400M -114.55400M -63.78200M -45.39600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALLK
Allakos Inc		 0.18 17.29% 1.25 - - - 1.41 - -0.5048
NVO
Novo Nordisk A/S		 -2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Inc

825 Industrial Road, San Carlos, CA, United States, 94070

Key Executives

Name Title Year Born
Dr. Robert Alexander Ph.D. CEO & Director 1970
Dr. Adam L. Tomasi Ph.D. Pres & COO 1970
Mr. Baird Radford III Chief Financial Officer NA
Dr. Henrik Sandvad Rasmussen Strategic Advisor 1959
Dr. Craig Paterson M.D. Chief Medical Officer NA
Brad Youngblood Head of Research NA
Mr. Alan Chang Director of Medical Affairs & Data Analytics NA
Dr. Adam L. Tomasi Ph.D. President 1970
Mr. Baird Radford III Chief Financial Officer 1970
Ms. Mary Cromwell Ph.D. Chief Technical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.